EsoBiotec - About the company
EsoBiotec is an acquired company based in Mont-Saint-Guibert (Belgium), founded in 2020. It operates as a Developer of in vivo adoptive cell therapies for cancer and autoimmune diseases. This involves engineering immune cells directly within the patient's body, eliminating the need for complex ex vivo manufacturing and reducing the risks associated with traditional cell therapies. The company utilizes a proprietary vector platform to enable single-injection, off-the-shelf treatments, simplifying treatment logistics and reducing costs. The therapies are designed to minimize immune rejection and graft-versus-host disease, improving patient accessibility and quality of life. The platform is scalable, ensuring high-yield and high-purity production.. EsoBiotec has raised $2.15M in funding from investors like Thuja Capital, Sambrinvest and UCB Ventures. The company has 3627 active competitors, including 1201 funded and 819 that have exited. Its top competitors include companies like BeiGene, Jazz Pharmaceuticals and Kite Pharma.
Company Details
{}
Key Metrics
Founded Year
2020
Location
Mont-Saint-Guibert, Belgium
Stage
Acquired
Total Funding
$2.15M in 2 rounds
Latest Funding Round
Investors
Ranked
535th among 3627 active competitors
Employee Count
7 as on Sep 30, 2026
Exit Details
Acquired by AstraZeneca (Mar 17, 2025)
Legal entities associated with EsoBiotec
EsoBiotec is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
EsoBiotec CIN: 0756.885.159 , Belgium, Active | Oct 21, 2020 | - | 8 (As on Dec 31, 2022) | - |
EsoBiotec's acquisition details
EsoBiotec got acquired by AstraZeneca on Mar 17, 2025 at an acquisition amount of $*****.
Click here to take a look at EsoBiotec's acquisition in detail
Sign up to download EsoBiotec's company profile
EsoBiotec's funding and investors
EsoBiotec has raised a total funding of $2.15M over 2 rounds. Its first funding round was on 2021. Its latest funding round was a Series A round on Dec 11, 2023 for $*****. 1 investor participated in its latest round. EsoBiotec has 7 institutional investors.
Here is the list of recent funding rounds of EsoBiotec:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 11, 2023 | 9807664 | Series A | 1842886 | 6275224 | 8828831 | 6672215 |
2021 | 2376 | Seed | 4025 | 4166 | 4892 |
View details of EsoBiotec's funding rounds and investors
EsoBiotec's founders and board of directors
Founder? Claim ProfileEsoBiotec's employee count trend
EsoBiotec has 7 employees as of Sep 26. Here is EsoBiotec's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
EsoBiotec's Competitors and alternates
Top competitors of EsoBiotec include BeiGene, Jazz Pharmaceuticals and Kite Pharma. Here is the list of Top 10 competitors of EsoBiotec, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
2nd | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
3rd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 76/100 | |
4th | Attovia 2023, Fremont (United States), Public | Developer of antibody-based therapeutics for immune-mediated diseases and oncology | $255M | 72/100 | |
5th | Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th | Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
8th | Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
9th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
10th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
535th | Developer of in vivo adoptive cell therapies for cancer and autoimmune diseases. This involves engineering immune cells directly within the patient's body, eliminating the need for complex ex vivo manufacturing and reducing the risks associated with traditional cell therapies. The company utilizes a proprietary vector platform to enable single-injection, off-the-shelf treatments, simplifying treatment logistics and reducing costs. The therapies are designed to minimize immune rejection and graft-versus-host disease, improving patient accessibility and quality of life. The platform is scalable, ensuring high-yield and high-purity production. | $2.15M | 52/100 |
Looking for more details on EsoBiotec's competitors? Click here to see the top ones
EsoBiotec's Investments and acquisitions
EsoBiotec has made no investments or acquisitions yet.
Reports related to EsoBiotec
Here is the latest report on EsoBiotec's sector:
News related to EsoBiotec
Media has covered EsoBiotec for 1 event in last 1 year.
•
Pfizer and Merck's clinical trials in China investigated: Cost reductions of up to 60%, even the FDA couldn't stop it.TMTpost•Jul 09, 2026•EsoBiotec
•
AstraZeneca Completes Acquisition of EsoBiotec for Up to $1 BillionCision•May 20, 2025•AstraZeneca, EsoBiotec
•
•
AstraZeneca’s $1 Billion Acquisition of EsoBiotecGlobal Legal Chronicle•Mar 27, 2025•Covington & Burling, AstraZeneca, EsoBiotec
•
AstraZeneca to pay up to US$1 billion for startup that may revolutionize cancer treatmentExame•Mar 17, 2025•AstraZeneca, EsoBiotec
•
•
Astrazeneca Stock: Billion-dollar Biotech Acquisition Enhances PortfolioAktiencheck•Mar 17, 2025•AstraZeneca, EsoBiotec
•
•
AstraZeneca to buy biotechnology company for up to $1bnInsider Media•Mar 17, 2025•AstraZeneca, EsoBiotec
•
Esobiotec To Be Acquired By Astrazeneca To Advance Cell Therapy AmbitionBenzinga•Mar 17, 2025•EsoBiotec, AstraZeneca
Are you a Founder ?
FAQs about EsoBiotec
Explore our recently published companies
- Silicon Color - Bangkok based, Unfunded company
- Protelligence - Pfaffenhofen An Der Roth based, 2025 founded, Unfunded company
- Hyperstate AI - Beverly Hills based, Unfunded company
- CoBooCo - Harrow based, 2010 founded, Unfunded company
- BarBlackBook - 2009 founded, Unfunded company
- Clyronex - South Africa based, 2016 founded, Unfunded company